Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain
Lexicon Pharmaceuticals (NASDAQ: LXRX) convened a stakeholder roundtable on Oct 8, 2025 at BIO headquarters to discuss public policy gaps for people with chronic pain and options to expand the Alternatives to PAIN Act to include chronic pain.
Participants included clinicians, patient advocates, and individuals affected by pain. The meeting cited U.S. Pain Foundation estimates of ~50 million Americans with chronic pain and costs of up to $635 million annually. Lexicon said it will publish a White Paper summarizing the roundtable outcomes and advocated for broader Medicare Part D access to non-opioid therapies beyond acute and post‑surgical pain.
Lexicon Pharmaceuticals (NASDAQ: LXRX) ha convocato un tavolo di stakeholder il 8 ottobre 2025 presso la sede di BIO per discutere lacune nelle politiche pubbliche per le persone affette da dolore cronico e le opzioni per ampliare l'Alternatives to PAIN Act per includere il dolore cronico.
Tra i partecipanti vi erano clinici, sostenitori dei pazienti e individui colpiti dal dolore. L'incontro ha citato stime della U.S. Pain Foundation di circa 50 milioni di americani con dolore cronico e costi fino a $635 milioni all'anno. Lexicon ha detto che pubblicherà un White Paper riassuntivo degli esiti del tavolo e ha sostenuto un miglior accesso al Medicare Part D per terapie non opioidiche oltre al dolore acuto e post-operatorio.
Lexicon Pharmaceuticals (NASDAQ: LXRX) convocó una mesa redonda de interesados el 8 de octubre de 2025 en la sede de BIO para discutir brechas de políticas públicas para las personas con dolor crónico y opciones para ampliar la Alternatives to PAIN Act para incluir el dolor crónico.
Entre los participantes había clínicos, defensores de pacientes e individuos afectados por el dolor. La reunión citó estimaciones de la U.S. Pain Foundation de ~50 millones de estadounidenses con dolor crónico y costos de hasta $635 millones anuales. Lexicon indicó que publicará un White Paper resumiendo los resultados de la mesa redonda y abogó por un acceso más amplio a Medicare Part D para terapias no opioides más allá del dolor agudo y postoperatorio.
Lexicon Pharmaceuticals (NASDAQ: LXRX) 는 2025년 10월 8일 BIO 본사에서 이해관계자 원탁회의를 소집하여 만성 통증 환자를 위한 공공정책의 격차와 만성 통증을 포함하도록 Alternatives to PAIN Act를 확장하는 옵션을 논의했습니다.
참여자에는 임상 의사, 환자 옹호자 및 통증으로 고통받는 사람들이 포함되었습니다. 회의는 만성 통증을 가진 미국인 약 5천만 명과 연간 비용이 $635백만에 달한다는 미국 통증 재단의 추정치를 인용했습니다. Lexicon은 원탁회의 결과를 요약하는 화이트 페이퍼를 발표하고 만성 통증 치료에 비마약 치료의 Medicare Part D 접근 확대를 주장했습니다.
Lexicon Pharmaceuticals (NASDAQ: LXRX) a réuni une table ronde avec les parties prenantes le 8 octobre 2025 au siège de BIO pour discuter des lacunes des politiques publiques pour les personnes souffrant de douleur chronique et des options pour étendre l'Alternatives to PAIN Act afin d'inclure la douleur chronique.
Les participants comprenaient des cliniciens, des défenseurs des patients et des personnes touchées par la douleur. La réunion a cité les estimations de la U.S. Pain Foundation d’environ 50 millions d’Américains souffrant de douleur chronique et des coûts allant jusqu’à $635 millions par an. Lexicon a annoncé qu’elle publierait un White Paper résumant les résultats de la table ronde et a préconisé un accès plus large à Medicare Part D pour les thérapies non opioïdes au-delà de la douleur aiguë et post-opératoire.
Lexicon Pharmaceuticals (NASDAQ: LXRX) hat am 8. Oktober 2025 eine Stakeholder-Runde im BIO-Hauptsitz einberufen, um Lücken in der öffentlichen Politik für Menschen mit chronischen Schmerzen und Optionen zur Erweiterung des Alternatives to PAIN Act zu diskutieren, um chronische Schmerzen einzubeziehen.
Zu den Teilnehmern gehörten Kliniker, Patientenvertreter und von Schmerzen Betroffene. Das Treffen zitierte Schätzungen der U.S. Pain Foundation von ca. 50 Millionen Amerikanern mit chronischen Schmerzen und Kosten von bis zu $635 Millionen pro Jahr. Lexicon sagte, sie werde ein White Paper veröffentlichen, das die Ergebnisse der Runde zusammenfasst, und plädierte für einen breiteren Zugang zu Medicare Part D zu nicht-opioiden Therapien über akute und postoperativ Schmerzen hinaus.
Lexicon Pharmaceuticals (NASDAQ: LXRX) عقدت مائدة مستديرة لأصحاب المصلحة في 8 أكتوبر 2025 في مقر BIO لمناقشة الثغرات في السياسة العامة للأشخاص المصابين بالألم المزمن وخيارات توسيع Alternatives to PAIN Act لتشمل الألم المزمن.
شارك في اللقاء أطباء ومناصرون للمرضى وأشخاص يعانون من الألم. استشهد الاجتماع بتقديرات مؤسسة U.S. Pain Foundation التي تقدر حوالي 50 مليون أميركي يعانون من الألم المزمن وتكاليف تصل إلى $635 مليون سنوياً. قالت Lexicon إنها ستنشر ورقة بيضاء تلخص نتائج المائدة وتدعو إلى توسيع الوصول إلى Medicare Part D لعلاجات غير مخدّرة إلى ما وراء الألم الحاد وما بعد الجراحة.
Lexicon Pharmaceuticals (NASDAQ: LXRX) 于 2025年10月8日 在 BIO 总部召开了一场利益相关者圆桌会议，讨论慢性疼痛人群的公共政策缺口以及将 Alternatives to PAIN Act 扩展以包含慢性疼痛的选项。
参与者包括临床医生、患者倡导者和受疼痛影响的个人。会议引用了 U.S. Pain Foundation 的估计，约有 5000万 名慢性疼痛美国人，年度成本高达 $635 百万。Lexicon 表示将发布一份 White Paper 总结圆桌会议结果，并主张扩大 Medicare Part D 覆盖非阿片类治疗，超越急性痛和术后疼痛。
- None.
- None.
Diverse group of stakeholders aligned around the importance of elevating public awareness of need for new treatments for chronic pain and the need to expand the Alternatives to PAIN Act
THE WOODLANDS, Texas, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Yesterday, Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) hosted and participated in a roundtable discussion with experts to explore how to enhance current and future legislative and policy efforts to better meet the needs of Americans suffering from chronic pain. The perspectives of clinicians, patient advocacy groups, and individuals were shared during the half-day meeting conducted at the Biotechnology Innovation Organization (BIO) headquarters in Washington, DC.
According to the U.S. Pain Foundation, approximately 50 million Americans suffer from chronic pain and pain conditions cost as much as
The roundtable participants focused primarily on the Alternatives to PAIN Act, introduced earlier this year in both houses of Congress. The bill aims to provide greater access to non-opioid pain treatments under Medicare Part D, but currently only for those with acute or post-surgical pain. The roundtable discussed potential ways to include people suffering from chronic pain in important pieces of legislation, such as the Alternatives to PAIN Act.
“The group acknowledged the importance of innovation in pain treatment, as pain is still a severely undertreated and not fully understood condition,” said Mike Exton, Ph.D., Lexicon’s chief executive officer and director. “Novel, non-opioid therapies can provide important treatment alternatives for people suffering from pain, including those with chronic pain conditions. Although the Alternatives to PAIN Act is limited to acute and post-surgical pain, we are passionate about collectively advocating for the expansion of this crucial bill to include chronic pain.”
Lexicon plans to produce and distribute a White Paper on chronic pain and the outcomes of this week’s roundtable.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to treat disease safely and effectively. Lexicon has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity, metabolism and other indications. For additional information, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, including the commercialization of its approved products and the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of its other drug candidates, including sotagliflozin. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery, development and commercialization of products, strategic alliances and intellectual property, regulatory interactions relating to its drug candidates, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully commercialize its approved products, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of its other drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its approved products and other drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
For Investor and Media Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
FAQ
What did Lexicon (LXRX) announce on Oct 8, 2025 about chronic pain policy?
How does the Alternatives to PAIN Act currently treat chronic pain and what change did LXRX advocate?
Why is expanding non-opioid treatment access important according to Lexicon (LXRX)?
Will Lexicon (LXRX) publish details from the roundtable and when?
How might the proposed expansion to the Alternatives to PAIN Act affect Medicare Part D coverage?
